Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on January 13, 2022, reporting events occurring on January 12, 2022. The filing details the entry into a material definitive agreement involving the acquisition of assets and a strategic collaboration.
Key Financial Metrics and Transaction Details
The filing discloses a specific transaction structure rather than standard periodic financial metrics (revenue, profit, cash flow) for a reporting period.
- Transaction Type: Acquisition and Strategic Collaboration Agreement (ASCA) with DeuteRx, LLC.
- Assets Acquired: Rights to the development product DRX-164, related intellectual property, data, tangible materials, and goodwill.
- Upfront Purchase Price:
- Cash Payment: $1,500,000 USD.
- Equity Payment: 1,000,000 shares of Salarius Pharmaceuticals, Inc. common stock.
- Contingent Consideration: The agreement includes future Milestone Payments and Royalty Payments, though specific values or triggers are not detailed in this summary text.
Material Changes
The primary material change is the expansion of the Company's asset portfolio through the acquisition of DRX-164. The Company also entered into a concurrent R&D Services Agreement with the Seller to handle the Non-Clinical and Clinical Development Scope of Work for the acquired product.
Outlook, Risks, and Management Commentary
Management announced the transaction via a press release on January 13, 2022. The filing notes that the ASCA contains representations, warranties, and covenants made solely for the purposes of the agreement and should be read in conjunction with the Company's Forms 10-K and 10-Q. No specific forward-looking guidance regarding revenue or earnings was provided in this document.
Investor Verification Checklist
- Verify the exact terms of the Milestone Payments and Royalty Payments in the full text of Exhibit 10.1 (ASCA), as specific amounts are omitted here.
- Confirm the market value of the 1,000,000 shares issued on the transaction date to calculate the total equity consideration.
- Review the R&D Services Agreement to understand the ongoing financial obligations for the development scope of work.
- Check the Company's most recent 10-K or 10-Q to assess the impact of the $1.5 million cash outflow on current liquidity.
- Validate the regulatory status and development stage of the acquired asset, DRX-164.